Literature DB >> 1334560

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

R Kirnbauer1, F Booy, N Cheng, D R Lowy, J T Schiller.   

Abstract

Infection by certain human papillomavirus types is regarded as the major risk factor in the development of cervical cancer, one of the most common cancers of women worldwide. Analysis of the immunogenic and structural features of papillomavirus virions has been hampered by the inability to efficiently propagate the viruses in cultured cells. For instance, it has not been established whether the major capsid protein L1 alone is sufficient for virus particle assembly. In addition, it is not known whether L1, L2 (the minor capsid protein), or both present the immunodominant epitopes required for induction of high-titer neutralizing antibodies. We have expressed the L1 major capsid proteins of bovine papillomavirus type 1 and human papillomavirus type 16 in insect cells via a baculovirus vector and analyzed their conformation and immunogenicity. The L1 proteins were expressed at high levels and assembled into structures that closely resembled papillomavirus virions. The self-assembled bovine papillomavirus L1, in contrast to L1 extracted from recombinant bacteria or denatured virions, also mimicked intact bovine papillomavirus virions in being able to induce high-titer neutralizing rabbit antisera. These results indicate that L1 protein has the intrinsic capacity to assemble into empty capsid-like structures whose immunogenicity is similar to infectious virions. This type of L1 preparation might be considered as a candidate for a serological test to measure antibodies to conformational virion epitopes and for a vaccine to prevent papillomavirus infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334560      PMCID: PMC50722          DOI: 10.1073/pnas.89.24.12180

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Proteins present in bovine papillomavirus particles.

Authors:  P M Larsen; L Storgaard; S J Fey
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

2.  Self-assembly of purified polyomavirus capsid protein VP1.

Authors:  D M Salunke; D L Caspar; R L Garcea
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

3.  A quantitative in vitro focus assay for bovine papilloma virus.

Authors:  I Dvoretzky; R Shober; S K Chattopadhyay; D R Lowy
Journal:  Virology       Date:  1980-06       Impact factor: 3.616

4.  Identification of L2 open reading frame gene products of bovine papillomavirus type 1 using monoclonal antibodies.

Authors:  X W Jin; L M Cowsert; W P Pilacinski; A B Jenson
Journal:  J Gen Virol       Date:  1989-05       Impact factor: 3.891

5.  Monoclonal antibodies to genus- and type-specific papillomavirus structural antigens.

Authors:  Y Nakai; W D Lancaster; L Y Lim; A B Jenson
Journal:  Intervirology       Date:  1986       Impact factor: 1.763

6.  Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11.

Authors:  N D Christensen; J W Kreider; N M Cladel; S D Patrick; P A Welsh
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

7.  Bovine serological response to a recombinant BPV-1 major capsid protein vaccine.

Authors:  X W Jin; L Cowsert; D Marshall; D Reed; W Pilacinski; L Y Lim; A B Jenson
Journal:  Intervirology       Date:  1990       Impact factor: 1.763

8.  Immunization against bovine papillomavirus infection.

Authors:  W P Pilacinski; D L Glassman; K F Glassman; D E Reed; M A Lum; R F Marshall; C C Muscoplat; A J Faras
Journal:  Ciba Found Symp       Date:  1986

9.  Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission.

Authors:  C E Stevens; P E Taylor; M J Tong; P T Toy; G N Vyas; P V Nair; J Y Weissman; S Krugman
Journal:  JAMA       Date:  1987-05-15       Impact factor: 56.272

10.  Human papillomavirus type 16 DNA sequence.

Authors:  K Seedorf; G Krämmer; M Dürst; S Suhai; W G Röwekamp
Journal:  Virology       Date:  1985-08       Impact factor: 3.616

View more
  339 in total

1.  DNA-induced structural changes in the papillomavirus capsid.

Authors:  C Fligge; F Schäfer; H C Selinka; C Sapp; M Sapp
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay.

Authors:  Kevin L Karem; Alysia C Poon; Cynthia Bierl; Rosane Nisenbaum; Elizabeth Unger
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

3.  Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Authors:  R B Roden; P M Day; B K Bronzo; W H Yutzy; Y Yang; D R Lowy; J T Schiller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 4.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

5.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

6.  Further evidence that papillomavirus capsids exist in two distinct conformations.

Authors:  Hans-Christoph Selinka; Tzenan Giroglou; Thorsten Nowak; Neil D Christensen; Martin Sapp
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 7.  The development of vaccines: how the past led to the future.

Authors:  Stanley A Plotkin; Susan L Plotkin
Journal:  Nat Rev Microbiol       Date:  2011-10-03       Impact factor: 60.633

Review 8.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

9.  Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors:  Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.